Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression.

Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression.

<p>The cell populations are healthy marrow cells (<i>A</i>), CD38+ cancer and CD38− cancer , and all arrows represent movement of cells between populations or states. Three drug actions are included (green arrows): cell mortality and loss of CD38 expression in the CD38+ cancer cell...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile nagusia: James G. Lefevre (11303976) (author)
Beste egile batzuk: Brodie A. J. Lawson (8771843) (author), Pamela M. Burrage (16938568) (author), Diane M. Donovan (22033185) (author), Kevin Burrage (21168) (author)
Argitaratua: 2025
Gaiak:
Biophysics
Biochemistry
Medicine
Genetics
Pharmacology
Biotechnology
Cancer
Hematology
Infectious Diseases
Biological Sciences not elsewhere classified
target drug effects
plasma cell cancer
monoclonal antibody daratumumab
target drug effect
healthy cells due
cd38 expression switches
optimal treatment regime
drug resistance mechanisms
healthy cells
drug action
cd38 expression
cancer cells
optimal treatment
added mechanisms
optimal control
myeloma cells
leading treatment
express cd38
daratumumab treatment
cd38 receptor
proposed mechanism
ode model
lower fitness
indirect effect
identified within
highly overexpressed
general increase
direct effect
bone marrow
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak